Lenvatinib in Locally Advanced Invasive Thyroid Cancer

Status Recruiting

Clinical Trial Summary

This research is being done to evaluate the safety and efficacy of neoadjuvant lenvatinib on surgical outcomes of patients with invasive extrathyroidal differentiated thyroid cancer (DTC). This research study involves a study drug called lenvatinib

Clinical Trial Description

This is a multicenter, phase II, open-label study examining the effect of neoadjuvant lenvatinib being given to patients with extrathyroidal differentiated thyroid cancer (DTC) prior to surgery to remove cancerous tumors (thyroidectomy). - The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits. - This research study involves a study drug called lenvatinib. - It is anticipated that 30 people will participate in the study. The U.S. Food and Drug Administration (FDA) has not approved lenvatinib for the specific disease of extrathyroidal differentiated thyroid cancer (DTC) but it has been approved for other uses. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04321954
Study type	Interventional
Source	Massachusetts Eye and Ear Infirmary
Contact	Gregory Randolph, MD
Phone	617-573-4115
Email	Gregory_Randolph@MEEI.harvard.edu
Status	Recruiting
Phase	Phase 2
Start date	March 9, 2021
Completion date	March 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03181854` - Randomized Controlled Trial of Integrated Early Palliative Care	N/A
Completed	`NCT01197170` - Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance	Phase 1
Recruiting	`NCT05045040` - Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions	N/A
Active, not recruiting	`NCT05060432` - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT03994601` - An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers	Phase 1/Phase 2
Active, not recruiting	`NCT03667716` - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.	Phase 1
Completed	`NCT01393990` - A Study of LY2228820 in Participants With Advanced Cancer	Phase 1
Completed	`NCT02857270` - A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer	Phase 1
Recruiting	`NCT03175224` - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Phase 2
Active, not recruiting	`NCT04121676` - Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer	Phase 1
Active, not recruiting	`NCT03177291` - Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC	Phase 1
Completed	`NCT03980041` - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)	Phase 2
Active, not recruiting	`NCT03674567` - Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab	Phase 1/Phase 2
Recruiting	`NCT04823377` - Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.	N/A
Completed	`NCT02778126` - A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer	Phase 1
Completed	`NCT02507544` - A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer	Phase 1
Completed	`NCT02529553` - A Study of LY3076226 in Participants With Advanced or Metastatic Cancer	Phase 1
Completed	`NCT02245204` - Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers	Phase 1
Terminated	`NCT01929941` - An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies	Phase 1
Completed	`NCT01583777` - Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer	Phase 1